35 results on '"Nagayama, Ayako"'
Search Results
2. Preserved seasonal variation in glycemic control in patients with type 2 diabetes mellitus during COVID-19: a 3-year-long retrospective cohort study in older adults in Japan
3. Mitochondrial fission is required for thermogenesis in brown adipose tissue.
4. Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes
5. Quinacrine is not a vital fluorescent probe for vesicular ATP storage
6. Successful Superficial Blood Sampling to Localize a Fibroblast Growth Factor-23-Producing Tumor
7. 肝細胞癌に対するatezolizumab＋bevacizumab併用療法後に出現した下垂体性副腎皮質機能低下症の3症例
8. Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury
9. Thyroid-related ophthalmopathy development in concurrence with growth hormone administration
10. Metyrosine-associated endocrinological changes in pheochromocytoma or paraganglioma
11. IgG4-Related Membranous Nephropathy with Acute Nephrotic Syndrome During Successful Steroid Maintenance Treatment for Type 1 Autoimmune Pancreatitis
12. Identification of substances which regulate activity of corticotropin-releasing factor-producing neurons in the paraventricular nucleus of the hypothalamus
13. Iliopsoas muscle to visceral fat ratio on CT predicts Cushing’s syndrome in elderly females with adrenal tumors
14. Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM
15. Eruptive xanthomas as a marker for metabolic disorders: A specific form of xanthoma that reflects hypertriglyceridemia
16. Case Report: Myxedema Coma Caused by Immunoglobulin A Vasculitis in a Patient With Severe Hypothyroidism
17. Eruptive xanthomas as a marker for metabolic disorders: A specific form of xanthoma that reflects hypertriglyceridemia
18. Additional file 1 of Thyroid-related ophthalmopathy development in concurrence with growth hormone administration
19. Additional file 2 of Thyroid-related ophthalmopathy development in concurrence with growth hormone administration
20. An Open-label Phase I/IIa Clinical Trial of 11β-HSD1 Inhibitor for Cushing’s Syndrome and Autonomous Cortisol Secretion
21. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
22. Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes
23. Masked Diabetes Insipidus Hidden by Severe Hyponatremia: A Case of Pituitary Metastasis of Lung Adenocarcinoma
24. Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
25. Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
26. Isolation and Structure Determination of a Heat Shock Protein Inducer, Asparagus-Derived Proline-Containing 3-Alkyldiketopiperazines (Asparaprolines), From a Standardized Extract of Asparagus officinalis Stem
27. Necessity of Utilizing Physiological Glucocorticoids for Managing Familial Mediterranean Fever
28. Supplemental Table: The reference list of case reports on autoimmune polyendocrine syndrome type 3 with myasthenia gravis, which were either written in Japanese or presented at conferences held in Japan
29. Metreleptin for acquired diabetes lipodystrophy
30. Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3
31. Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report
32. 11[beta]-HSD type 1 inhibitor ameliorates metabolic disorders associated with hypercortisolemia: A clinical trial to assess its safety and efficacy in Japanese patients with refractory Cushing's syndrome and subclinical Cushing's syndrome
33. Effect of SGLT2 Inhibition on Body Water Distribution and Its Relevance to Body Composition Measures
34. Assessing the Metabolic and Physical Effects of Combined DPP4 and SGLT2 Inhibitor Therapy in Patients with Type-2 Diabetes Mellitus: An Observational Prospective Pilot Study.
35. Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.